Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;100(8):1467-1470.
doi: 10.1002/ajh.27733. Epub 2025 Jun 5.

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database

Fabio Stagno  1 , Rosalba Cucci  2 , Giovanni Marsili  2 , Fausto Castagnetti  3 , Sara Galimberti  4 , Barbara Izzo  5 , Federica Sorà  6 , Simona Soverini  3 , Monica Messina  2 , Alfonso Piciocchi  2 , Massimiliano Bonifacio  7 , Daniela Cilloni  8 , Alessandra Iurlo  9 , Giovanni Martinelli  3 , Gianantonio Rosti  10 , Paola Fazi  2 , Marco Vignetti  2 , Massimo Breccia  11 , Alessandro Allegra  1 , Fabrizio Pane  12
Affiliations

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database

Fabio Stagno et al. Am J Hematol. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

F.S.: Incyte, Novartis, Janssen; F.C.: Novartis, Incyte; S.G.: Roche, Incyte, Novartis, Jazz, AstraZeneca, AbbVie, Celgene, Pfizer, Janssen; F.S.: Novartis; S.S.: Blueprint Medicines, Incyte, Istituto Gentili; M.B.: Pfizer, Amgen, Incyte, Novartis, BMS; G.M.: Novartis, BMS, ARIAD, MSD, Roche, Pfizer; G.R.: Pfizer, Novartis, Incyte; M.V.: Mattioli Health, Arhea, Edrea, Vertex, Isheo, Novartis, Abbvie, AstraZeneca, Dephaforum SRL; M.B.: GSK, BMS, Abbvie, AOP, Incyte, Pfizer, Novartis; F.P.: GSK, Incyte, Amgen, BMS, Janssen, Jazz, Novartis, Pfizer, GSK, Incyte. The other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Consort diagram of the total CML population.
See this image and copyright information in PMC

References

    1. Hochhaus A., Baccarani M., Silver R. T., et al., “European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia,” Leukemia 34, no. 4 (2020): 966–984, 10.1038/s41375-020-0776-2. - DOI - PMC - PubMed
    1. Hughes T. P. and Ross D. M., “Moving Treatment‐Free Remission Into Mainstream Clinical Practice in CML,” Blood 128, no. 1 (2016): 17–23, 10.1182/blood-2016-01-694265. - DOI - PubMed
    1. Mahon F. X., “Discontinuation of TKI Therapy and ‘functional’ Cure for CML,” Best Practice & Research Clinical Haematology 29, no. 3 (2016): 308–313, 10.1016/j.beha.2016.10.014. - DOI - PubMed
    1. Hughes T. P., Yong A. S., and Ross D. M., “The Evolution of Treatment‐Free Remission,” Blood 145, no. 9 (2025): 921–930. - PubMed
    1. Stagno F., Breccia M., and Di Raimondo F., “On the Road to Treatment‐Free Remission in Chronic Myeloid Leukemia: What About ‘the Others’?,” Expert Review of Anticancer Therapy 20, no. 12 (2020): 1075–1081, 10.1080/14737140.2020.1829483. - DOI - PubMed

Grants and funding

LinkOut - more resources